First Time Loading...

Cytodyn Inc
OTC:CYDY

Watchlist Manager
Cytodyn Inc Logo
Cytodyn Inc
OTC:CYDY
Watchlist
Price: 0.1666 USD 0.97% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of CYDY.

Key Points:
CYDY Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

Financials

Balance Sheet Decomposition
Cytodyn Inc

Current Assets 10.8m
Cash & Short-Term Investments 2.5m
Other Current Assets 8.3m
Non-Current Assets 487k
PP&E 400k
Other Non-Current Assets 87k
Current Liabilities 119.8m
Accounts Payable 62.7m
Accrued Liabilities 22.6m
Other Current Liabilities 34.5m
Non-Current Liabilities 997k
Long-Term Debt 714k
Other Non-Current Liabilities 283k
Efficiency

Earnings Waterfall
Cytodyn Inc

Revenue
0 USD
Cost of Revenue
-20.6m USD
Gross Profit
-20.6m USD
Operating Expenses
-19.9m USD
Operating Income
-40.6m USD
Other Expenses
-39.2m USD
Net Income
-79.8m USD

Free Cash Flow Analysis
Cytodyn Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CYDY Profitability Score
Profitability Due Diligence

Cytodyn Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Exceptional ROE
Exceptional ROIC
55/100
Profitability
Score

Cytodyn Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

CYDY Solvency Score
Solvency Due Diligence

Cytodyn Inc's solvency score is 21/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
21/100
Solvency
Score

Cytodyn Inc's solvency score is 21/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYDY Price Targets Summary
Cytodyn Inc

There are no price targets for CYDY.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CYDY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CYDY Price
Cytodyn Inc

1M 1M
+4%
6M 6M
-7%
1Y 1Y
-56%
3Y 3Y
-92%
5Y 5Y
-65%
10Y 10Y
-79%
Annual Price Range
0.1666
52w Low
0.1521
52w High
0.38
Price Metrics
Average Annual Return 114.3%
Standard Deviation of Annual Returns 280.91%
Max Drawdown -98%
Shares Statistics
Market Capitalization 155.1m USD
Shares Outstanding 986 060 000
Percentage of Shares Shorted
N/A

CYDY Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cytodyn Inc Logo
Cytodyn Inc

Country

United States of America

Industry

Biotechnology

Market Cap

155.1m USD

Dividend Yield

0%

Description

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. The company is headquartered in Vancouver Washington, Washington and currently employs 24 full-time employees. The company went IPO on 2005-11-17. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. The CCR5 receptor is also the co-receptor needed for certain strains of human immunodeficiency virus (HIV) to infect healthy T-cells. The firm also completed a Phase IIb/III investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. The firm is also conducting a Phase II clinical trial with leronlimab in metastatic Triple Negative Breast Cancer (mTNBC), a Phase II basket trial in solid tumor cancers (22 different cancer indications), Phase II investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 long haulers, and a Phase II clinical trial for nonalcoholic steatohepatitis (NASH).

Contact

WASHINGTON
Vancouver Washington
1111 Main St Ste 660
+13609808524.0
https://www.cytodyn.com/

IPO

2005-11-17

Employees

24

Officers

Senior Vice President of Business Operations
Dr. Cyrus Arman M.B.A., Ph.D.
CEO & Member of Scientific Advisory Board
Dr. Jacob P. Lalezari M.D.
Interim Chief Financial Officer
Mr. Mitchell Cohen
Executive Vice President of Legal Affairs & Secretary
Mr. Tyler Blok
Head of Research & Basic Science
Dr. Scott Hansen Ph.D.
Executive Director of Clinical Operations
Mr. Joseph Meidling
Show More
Investors
Ms. Cristina De Leon
Show Less

See Also

Discover More